YES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
|
|
- Clifford Fleming
- 5 years ago
- Views:
Transcription
1 Stage I: Rule-Out Dashboard GENE/GENE PANEL: GAA DISORDER: Glycogen storage disease II (GSD2) HGNC ID: 4065 OMIM ID: ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? YES NO 2. Does the practice guideline or systematic review indicate that the result is actionable in one or more of the following ways? Yes No Patient Management Surveillance or Screening 4. Is there at least one known pathogenic variant with at least moderate penetrance ( 40%) or moderate relative risk ( 2) in any population? YES NO UNKNOWN SIGNIFICANCE/BURDEN OF DISEASE 5. Is this condition an important health problem? YES NO Family Management Circumstances to Avoid YES ( 1 of above) NO NEXT STEPS 6. Are Actionability (Q2-3), Penetrance (Q4), and Significance (Q5) all YES? 3. Is the result actionable in an undiagnosed adult with the genetic condition? YES NO YES (Proceed to Stage II) NO (Consult Actionability Working Group) Exception granted, proceed to Stage II Exception not granted, STOP 1
2 Significance/Burden of Condition GENE/GENE PANEL: GAA DISORDER: Glycogen storage disease II (GSD2) Topic Narrative Description of Evidence Ref 1. What is the nature of the threat to health for an individual carrying a deleterious allele? Prevalence of the genetic disorder The combined incidence of all forms of glycogen storage disease type II (GDS2, also known as Pompe disease) varies, depending on ethnicity and geographic region, from 1/14,000 in African Americans to 1/600,000 in Portugal. The combined incidence in the US is 1/40,000. The incidence of late-onset disease has been estimated as 1/57,000 in the Netherlands and 1/60,000 in individuals of European descent. GSD2 is a lysosomal storage disorder that results in the accumulation of glycogen in multiple tissues (most prominently skeletal, cardiac, and smooth muscle). GSD2 is progressive and can be classified into two general subtypes based on age of onset, clinical findings, severity, and rate of progression. In infantile-onset GSD2, GAA enzyme activity is completely or nearly completely absent (<1% of normal activity), while some residual activity (~2-40% of normal activity) is present in the late-onset form. (1-4) (1-6) Clinical Features (Signs/symptoms) The classic infantile-onset form is more severe and is characterized by cardiomegaly with respiratory distress, muscular hypotonia, and feeding difficulties. The non-classic variant of the infantile-onset form is typically less severe and presents with motor delays and/or muscle weakness. The late-onset form is characterized by progressive proximal muscle weakness, particularly in the trunk and lower limbs, and respiratory insufficiency without clinically apparent cardiac involvement. However, some adults with late-onset disease have been found to have arteriopathy. Ectasia of the basilar and internal carotid arteries has been noted, and may be associated with clinical signs, such as transient ischemic attacks and 3rd nerve paralysis. In addition, dilation of the ascending thoracic aorta has been noted. Intracranial aneurysms may be present in some patients leading to subarachnoid hemorrhage. Other features may include exercise intolerance, exertional dyspnea, orthopnea, sleep apnea, hyperlordosis and/or scoliosis (childhood and juvenile onset), hepatomegaly (childhood and juvenile onset), macroglossia (childhood onset), difficulty chewing and swallowing, weak cough, increased respiratory infections, decreased deep tendon reflexes, Gower sign, joint contractures, cardiac hypertrophy (childhood onset), and developmental delay in motor skills (childhood onset). The classic infantile-onset form typically presents in the first 2 months of life. Without treatment by enzyme replacement therapy (ERT), it rapidly progresses and commonly results in death in the first year of life due to progressive left ventricular outflow obstruction. The non-classic variant of infantile-onset usually presents within the first year of life, has a slower progression, and typically results in death from ventilatory failure in early childhood. (1-7) Natural History (Important subgroups & survival/recovery) The late-onset form can present at variable ages, from early childhood (after age one) into adulthood (as late at the 7 th decade of life). The median age at diagnosis has been estimated as 38 years, though some affected adults often describe symptoms beginning in childhood. Progression of the disease is slower than the infantile-onset form and is often predicted by the age of onset and residual enzyme activity. The presenting symptom in 93% of patients is weakness of proximal extremities (generally preceded by myalgia and muscle cramps). Progression of skeletal muscle involvement eventually involves the diaphragm and accessory respiratory muscles. Roughly 60% of patients will have mild reduction in vital capacity and 30-40% will have moderate reduction. Affected individuals have a mean reduction in vital capacity of approximately 1.5% per year following diagnosis and the likelihood of needing either non-invasive or invasive ventilation increases by an average of 8% each year following diagnosis. Affected individuals often become wheelchair dependent because of lower limb weakness, with the probability of wheelchair use increasing, on average, 13% each year after diagnosis without treatment. Respiratory failure 2
3 causes the major morbidity and mortality of this form of the disease. Male gender, severity of skeletal muscle weakness, and duration of disease are all risk factors for severe respiratory insufficiency. The median age at death in untreated adults has been estimated as 55 years (range years). 2. How effective are interventions for preventing the harm? Information on the effectiveness of the recommendations below was not provided unless otherwise stated. The following evaluations should be performed at diagnosis (Tier 2): Echocardiogram 24-hour ambulatory ECG Assessment of pulmonary function and gas exchange Chest X-ray Polysomnography and detailed sleep history for sleep respiratory function Measure cardiorespiratory status and response to position and activity with pulse oximetry Screen for osteopenia/osteoporosis with dual-energy x-ray absorptiometry (DEXA) Assessment of musculoskeletal impairment and muscle strength Measures of function, disability, pain, and quality of life Perform neurology assessments including nerve conduction studies, needle electromyography (EMG) to determine presence of denervation as evidence of anterior horn cell involvement, and hearing tests. Management of patients should consist of a team including a physician with experience in managing GSD2 and specialists in the field of neurology, pulmonary, cardiology, orthopedics, metabolic dietician, general medicine, occupational therapists, and disease geneticists. (Tier 2) (3) (4, 5) Patient Management Though there are no established guidelines for muscle strengthening or therapeutic exercise for individuals with late-onset GSD2, a physical or occupational therapist should develop an exercise program with a focus on submaximal aerobic exercise and/or muscle strengthening, following guidelines for other degenerative muscle diseases. Functional activities should also be incorporated and strategies to optimize biomechanical advantage and use of energy conservation techniques. Although evidence is minimal (few studies with small sample sizes) in patients with GSD2, some studies suggest that submaximal exercise may increase muscle strength and function through improved clearance of accumulated glycogen in muscle. However, there is insufficient evidence that resistance training improves strength. (Tier 2) Little evidence is available for the effectiveness of muscle strengthening and therapeutic exercise in adult patients with GSD2. One study reported the results of a 12-week exercise intervention in adults mildly affected with GSD2 to improve aerobic fitness, muscle strength, and core stability. The study included 25 patients who had received ERT for at least one year and were not dependent on a ventilator and/or walking device. 23 patients completed the program and achieved decreased levels of fatigue and pain and improvements in endurance, muscle strength of the hip flexors and shoulder abductors, and core stability. However, no significant differences were observed in self-reported motor function or patient activity. (Tier 5) A systematic review of physiotherapy among patients with non-gsd2 neuromuscular disorders (e.g., muscular dystrophy) found that aerobic exercise (with or without strengthening exercises) had a positive effect on body function and activities and participation. However, inconsistent and insufficient evidence was found for the use of strengthening exercises alone. (Tier 5) No established guidelines exist for management of secondary musculoskeletal impairments, including contracture and deformity, in late-onset GSD2, though general principles established for the management of other neuromuscular disorders can be applied. These principles should be applied early and include limiting contracture and deformity by gentle daily stretching, correction of improper positioning, judicious and timely use of splints and orthotic interventions, and provision of adequate support in all positions, including sitting and (2, 3) (8, 9) (10) 3
4 supported standing. Prevention of contracture and deformity is critical to preserve function and limit other secondary complications, such as skin breakdown and chronic musculoskeletal pain. (Tier 2) Little evidence is available for the effectiveness of measures that manage secondary musculoskeletal impairments in adult patients with GSD2. However, gentle stretching, splinting, and bracing are effective in patients with Duchenne muscular dystrophy in slowing the development of contractures, maintaining joint extension, and extending walking time. (Tier 5) On the basis of a recent study showing a high prevalence of osteoporosis in patients with GSD2, all patients should undergo fall risk assessment. (Tier 2) Nutrition needs to be adequate in terms of intake of calcium, Vitamin D, and protein intake. (Tier 2) ERT with alglucosidase is the only specific treatment available for late-onset GSD2 in adults and children. However, it is not recommended for patients with no symptoms or objective signs (proximal muscle weakness or reduced FVC). ERT is recommended at the earliest onset of symptoms or objective signs. No clinical studies have yet been conducted to show whether the treatment of asymptomatic patients can delay the onset of symptoms of the disease. The Late- Onset Treatment Study (LOTS) is a randomized controlled trial for ERT that has been conducted in 90 patients aged 8 years and older. The results of the study indicate that ERT has a positive effect on the disease process or processes that produce impaired ambulation and respiratory insufficiency in late-onset GDS2. At week 78, statistically significant findings were reported with improvements in the 6-minute walk test (this improvement occurred in the first 26 weeks of treatment and maintained for the next 52 weeks) and percent of predicted upright FVC results among those administered ERT compared to those on placebo. An open label extension study indicated that improvements in walking distance and stabilization of pulmonary function noted at week 78 were maintained at week 104. However, it is unclear how these study endpoints translate into functional improvements for patients. Quality-of-life measures collected in the same study found no associated improvements. (Tier 2) A systematic review of mostly uncontrolled clinical studies of symptomatic ERT treatment summarized outcomes of 368 patients with late-onset GSD2, including 251 adults (age 18). Creatine kinase levels decreased in 70% of patients, stabilized in 11%, and increased in 20%. Motor performances improved in 78% of patients, stabilized in 8%, and declined in 14%. Of patients with impaired ambulatory status 6% had improvements following ERT treatment. Respiratory dysfunction improved in 52% of patients, stabilized in 14% and declined in 35%. Following treatment, 8% of patients reported an improvement in quality of life outcomes. (Tier 1) Given the increased risk of infections, strict hygiene and handwashing precautions should be implemented and medical attention should be sought for common symptoms such as a cough or fever. (Tier 2) Patients and other household contacts should stay up to date on vaccinations (particularly pneumococcus and influenza). (Tier 2) Early and aggressive treatment of bacterial and viral infections (particularly pulmonary infections) given the high risk for pneumonia and other infections that may lead to respiratory failure, intubation with ventilator dependence, and even death. Antivirals should be used for the flu. (Tier 2) General anesthesia must be performed by someone familiar with anesthesia in patients with GDS2 due to the risk of fatality. Surgical procedures must be grouped for a single anesthetic where possible. Intubation during surgery should be avoided, if possible. (Tier 2) (2, 3) (11) (2) (2-4) (2-4, 6) (7) (3-5) (2-5) (2-5) (3, 5) 4
5 Surveillance Family Management Circumstances to Avoid Pregnant women should undergo careful respiratory and cardiac surveillance in consultation with a maternal fetal medicine specialist. A growing fetus may pose additional complications for women with myopathy and respiratory insufficiency. (Tier 4) (1) The following assessments should be performed at regular intervals (Tier 2): (2, 3, 6) Chest X-ray Echocardiogram 24-hour ambulatory ECG to assess for life-threatening arrhythmias Monitor for arrhythmias Laboratory tests: serum creatinine kinase, transaminases, lactate dehydrogenase, and urinary hex4 Assess respiratory status at each visit Assess pulmonary function and gas exchange annually Measurement of maximal clearance of airway secretions Spirometry, pulse oximetry, capnography should routinely be performed Detailed sleep history and assessment of symptoms associated with sleep-disordered breathing to assess for respiratory dysfunction during sleep Other assessments, such as swallowing and neurological exams. Patients should be annually assessed for musculoskeletal impairments, functional deficits, levels of disability, and society participation. (Tier 2) When a presymptomatic patient is confirmed to have GSD2 through newborn screening, sibling screening, or another screening program, it is recommended that such patients be examined every 6 months and that muscle strength and pulmonary function (including FVC in both upright and supine positions) be monitored at these visits for the onset of symptoms to guide initiation of ERT. (Tier 2) All patients with GSD2 should be screened, regardless of age and wheelchair use, with DEXA with follow-up considered on a yearly basis. Low bone mineral density (BMD) is a common feature in patients, and a recent study demonstrated that 67% of the patients tested had a BMD z-score of -1 and that the decrease in BMD was present in both the infantile- and lateonset forms of the disease. (Tier 2) (2) Genetic counseling should be provided to all parents with an affected child with GSD2 and all adults with GSD2. DNA analysis is necessary for the identification of additional family members in the extended family who may be carriers. (Tier 2) (3, 4) Patients with GDS2 should avoid overwork weakness, excessive fatigue, disuse, strenuous exercises, and eccentric contractions. Excessively strenuous resistance exercises have been discouraged in muscle disorders due to the potential for exacerbating muscle degeneration. In GSD2, there is additional theoretical concern that excessive muscle contraction might lead to increased leakage of glycogen from lysosomes or cause lysosomal rupture, thereby hastening muscle damage. (Tier 2) (2, 3) Avoid drastic changes in fluid status, either through dehydration or fluid overload. (Tier 2) Patients should exercise caution when using some medications. Care should be taken with drugs that have a myorelaxant effect and central nervous system depressants. Some over the counter medications to treat cough, colds, and other symptoms often contain sympathomimetic agents which can be detrimental to the heart. The risk benefit ratio of use of medications such as steroids (risk of progressive muscle weakness and osteopenia) and loop diuretics (ototoxicity and calciuria) must be considered prior to administration. (Tier 2) (3) (2) (3) (2, 3) Description of sources of evidence: 5
6 Tier 1: Evidence from a systematic review, or a meta-analysis or clinical practice guideline clearly based on a systematic review Tier 2: Evidence from clinical practice guidelines or broad-based expert consensus with non-systematic evidence review Tier 3: Evidence from another source with non-systematic review of evidence with primary literature cited Tier 4: Evidence from another source with non-systematic review of evidence with no citations to primary data sources Tier 5: Evidence from a non-systematically identified source 6
7 GENE/GENE PANEL: GAA DISORDER: Glycogen storage disease II (GSD2) Topic Narrative Description of Evidence Ref 3. What is the chance that this threat will materialize? Mode of Inheritance Prevalence of Genetic Mutations Autosomal recessive The risk of being a heterozygous carrier of a mutation in the gene that causes GSD2 is approximately 1/100. (Tier 4) (4) Penetrance for individuals detected based on genotype was not identified. Information for patients detected clinically is listed below: Penetrance OR Relative Risk (include high risk racial or ethnic subgroups) Common findings in cases of infantile GSD2 (Tier 3): Hypotonia/muscle weakness= 52%-96% Cardiomegaly=92%-100% Hepatomegaly=29%-90% Left ventricular hypertrophy=83%-100% Cardiomyopathy=88% Respiratory distress=41%-78% Murmur=46%-75% Absent deep tendon reflexes=33%-35%. (1) Expressivity Findings in late-onset GSD2 (Tier 3): Progressive proximal muscle weakness=93-95% General fatigue and poor endurance=50-76% Muscle pain and soreness=46%. Information on relative risk was not available. Intergenerational phenotypic variation has been reported in several families with GSD2. (Tier 3) The clinical phenotype of late-onset GSD2 varies. (Tier 3) 4. What is the nature of the intervention? Nature of Intervention Preventive stretching regimens are better tolerated and accepted if they are initiated before muscle tendon tightness and contractures develop, a point at which stretching often becomes painful. Aggressive stretching should be approached cautiously because, at least in severely affected children, a tendency for pathologic fracture has been observed. In general, the use of ERT is safe. However, life-threatening anaphylactic reactions, severe allergic reactions, and immune-mediated reactions have been observed in some patients during ERT infusions. In the LOTS trial 5% of patients experienced an anaphylactic reaction. In an ERT trial, patients in the treatment and placebo groups had similar frequencies of adverse events, serious adverse events, and treatment-related adverse events. Most adverse events were mild to moderate and not considered to be related to the use of ERT. All ERT recipients tested negative for immunoglobulin G (IgG) anti-gaa antibodies at baseline, and all patients seroconverted by week 12. ERT is administered intravenously every 2 weeks; a device such as a port-a-cath may be implanted to make access easier. 5. Would the underlying risk or condition escape detection prior to harm in the setting of recommended care? Chance to Escape Clinical Detection The diagnosis of the late-onset form is often difficult because it can clinically resemble a myriad of other neuromuscular disorders. It can take several years to get a correct diagnosis, with one review finding a diagnostic delay ranging from 5 to 30 years. A high level of clinical suspicion is necessary for a timely and accurate diagnosis. (Tier 3) (1, 2) (1) (2) (2, 4) (2, 4) 7
8 Final Consensus Scores Gene(s) Outcome/intervention pair Severity Likelihood Effectiveness Nature of the Intervention GAA Musculoskeletal morbidity + Comprehensive care by a multidisciplinary team (includes physical therapy/exercise program, early treatment of infections, appropriate surveillance, etc.) Musculoskeletal morbidity + Enzyme replacement therapy Impaired pulmonary function + Enzyme replacement therapy Severe or life-threatening infections + Vaccination and aggressive prevention/treatment of infections Total Score 2 3C 1B 3 9CB 2 3C 2B 2 9CB 2 3C 2B 2 9CB 2 0D 1D 3 6DD To see the scoring key, please go to: Date of Search (MM.DD.YYYY): References 1. Leslie N, Tinkle BT. Glycogen Storage Disease Type II (Pompe Disease). In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA) Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3): ACMG Work Group on Management of Pompe Disease, Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5): Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez LM, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol. 2012;54(8): Bhengu L, Davidson A, du Toit P, Els C, Gerntholtz T, Govendrageloo K, et al. Diagnosis and management of Pompe disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2014;104(4): Wang RY, Bodamer OA, Watson MS, Wilcox WR, Diseases AWGoDCoLS. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011;13(5): Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. Journal of neurology. 2013;260(4): Favejee MM, van den Berg LE, Kruijshaar ME, Wens SC, Praet SF, Pim Pijnappel WW, et al. Exercise training in adults with Pompe disease: the effects on pain, fatigue, and functioning. Arch Phys Med Rehabil. 2015;96(5): van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, et al. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015;10: Cup EH, Pieterse AJ, Ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, et al. Exercise therapy and other types of physical therapy for patients with neuromuscular diseases: a systematic review. Arch Phys Med Rehabil. 2007;88(11): McDonald CM. Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery. Phys Med Rehabil Clin N Am. 1998;9(1):
9 9
Stage I: Rule-Out Dashboard Secondary Findings in Adults
Stage I: Rule-Out Dashboard GENE/GENE PANEL: DNM2 DISORDER: DNM2-Related Intermediate Charcot-Marie-Tooth Neuropathy HGNC ID: 2974 OMIM ID: 606482 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationLSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW. Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi
LSD WORKSHOP WHAT EVERY PEDIATRICIAN SHOULD KNOW Amal Al Tenaiji Pediatric Metabolic Genetics SKMC Abu Dhabi CASE A 1 month old infant presents with difficulty feeding and respiratory distress. Mom and
More informationMedication Policy Manual. Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015
Medication Policy Manual Policy No: dru392 Topic: Lumizyme, alglucosidase alfa Date of Origin: February 17, 2015 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: July
More informationYES NO UNKNOWN PENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES (Proceed to Stage II) YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ATP7B DISORDER: Wilson Disease HGNC ID: 870 OMIM ID: 277900 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 6998 OMIM ID: 134610 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TNNT2, LMNA HGNC ID: 11949, 6636 ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition?
More informationPompe. Lysosomal Disorders. Introduction
Introduction disease is an inherited, genetic disorder which results in the lack of an enzyme 'acid alpha-glucosidase. disease is also known as acid maltase deficiency or glycogen storage disease type
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: SMAD4, BMPR1A DISORDER: Juvenile Polyposis Syndrome HGNC ID: 6670, 1076 OMIM ID: 174900, 175050 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 11949, 6636, 2928 OMIM ID: 191045, 150330, 302045 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: LMNA, EMD, FHL1 DISORDER: Emery-Dreifuss Muscular Dystrophy (AD, XL) HGNC ID: 6636, 3331, 3702 OMIM ID: 181350, 310300, 300696 ACTIONABILITY PENETRANCE 1. Is
More informationStage I: Rule-Out Dashboard
Stage I: Rule-Out Dashboard GENE/GENE PANEL: GLA DISORDER: Fabry disease HGNC ID: 4296 OMIM ID: 301500 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic
More informationSCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE
SCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE 02 Changes in our lives can be stressful and leaving school and moving into the
More informationDEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE
DEVELOPING A FOLLOW-UP FRAMEWORK FOR POMPE DISEASE Presenter: Sarah Bradley, MS, CGC Genetic Counselor, NYS Newborn Screening Program Authors: S. Bradley, D. Kronn, B. Vogel, M. Caggana, J. Orsini, K.
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More information1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we?
Neuromuscular Disease: Muscular Dystrophy Muscular Dystrophy Association (MDA) and OSF HealthCare Illinois Neurological Institute (INI) Care Center Team The Neuromuscular clinic is a designated MDA Care
More informationUnderstanding Late-Onset Pompe Disease
Understanding Late-Onset Pompe Disease What Is a Lysosome? Millions of tiny units called cells make up the human body. Each cell has its own job to keep the body running. Within each cell, there are organelles,
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Duchenne and Becker Muscular Dystrophy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_duchenne_and_becker_muscular_dystrophy
More informationCARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY
IMPORTANT NEW UPDATE A Summary of the Report of the DMD Care Considerations Working Group Intended for US healthcare professionals only. CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY Full article
More informationDMD STANDARDS OF CARE
DMD STANDARDS OF CARE PPMD 2019 END DUCHENNE TOUR Russell Butterfield MD, PhD Director, Muscular Dystrophy Clinics Associate Professor University of Utah, School of Medicine February 2, 2019 DISCLOSURES
More informationDo Not Cite. For Public Comment Period DRAFT MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY
MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY Measure Description All patients diagnosed with a muscular dystrophy who had a pulmonary status evaluation* ordered. Measure Components
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: TTR DISORDER: Hereditary transthyretin-related amyloidosis HGNC ID: 12405 OMIM ID: 105210 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as
More informationStage I: Binning Dashboard
Stage I: Binning Dashboard P[ GENE/GENE PANEL: KCNQ1, KCNH2, SCN5A DISORDER: Romano-Ward Long QT Syndrome HGNC ID: 6294, 6251, 10593 OMIM ID: 192500, 613688, 603830 ACTIONABILITY PENETRANCE 1. Is there
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard HGNC ID: 9585 OMIM ID: 109400 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does
More informationPediatric Patients. Neuromuscular Disease. Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor
Patient Management Pediatric Patients with Neuromuscular Disease Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor Case Thai boy 1 year old Present with Respiratory
More informationSpinal Muscular Atrophy: Case Study. Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting
Spinal Muscular Atrophy: Case Study Spinal muscular atrophy (SMA) is a fairly common genetic disorder, affecting approximately one in 6,000 babies. It is estimated that one in every 40 Americans carries
More informationAppropriate Use Criteria for Initial Transthoracic Echocardiography in Outpatient Pediatric Cardiology (scores listed by Appropriate Use rating)
Appropriate Use Criteria for Initial Transthoracic Echocardiography in Outpatient Pediatric Cardiology (scores listed by Appropriate Use rating) Table 1: Appropriate indications (median score 7-9) Indication
More informationMuscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018
Muscular Dystrophies Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Definition and classification Clinical guide to recognize muscular
More informationPompe Disease. Family Education Booklet. Division of Pediatric Genetics Metabolism and Genomic Medicine
Pompe Disease Family Education Booklet Division of Pediatric Genetics Metabolism and Genomic Medicine Table of Contents What is Pompe disease?... 1 How common is Pompe disease?... 1 Basic genetic concepts...
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above)
Stage I: Rule-Out Dashboard GENE/GENE PANEL: ENG, ACVRL1, SMAD4, GDF2 DISORDER: Hereditary Hemorrhagic Telangiectasia HGNC ID: 3349, 175, 6770, 4217 OMIM ID: 187300, 600376, 175050, 615506 ACTIONABILITY
More informationThe 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy
Richard Finkel, MD Nemours Children s Hospital Orlando, FL, USA Thomas Crawford, MD Johns Hopkins Hospital Baltimore, MD, USA The 2017 Update of the Standard of Care Recommendations for Spinal Muscular
More informationPatient L.L. KRISTEN ARREDONDO, MD CHILD NEUROLOGY PGY5, UT SOUTHWESTERN
Patient L.L. KRISTEN ARREDONDO, MD CHILD NEUROLOGY PGY5, UT SOUTHWESTERN Birth History LL was born to a healthy first time mother with an uncomplicated pregnancy Delivered at 38 weeks via C-section due
More informationKENNEDY DISEASE PULMONARY CONSIDERATIONS: SCIENCE & MANAGEMENT STRATEGIES
KENNEDY DISEASE PULMONARY CONSIDERATIONS: SCIENCE & MANAGEMENT STRATEGIES When you can t breathe nothing else matters American Lung Association Noah Lechtzin, MD; MHS Associate Professor of Medicine Johns
More informationC1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders
C1: Medical Standards for Safety Critical Workers with Cardiovascular Disorders GENERAL ISSUES REGARDING MEDICAL FITNESS-FOR-DUTY 1. These medical standards apply to Union Pacific Railroad (UPRR) employees
More informationLearn the steps to identify pediatric muscle weakness and signs of neuromuscular disease.
Learn the steps to identify pediatric muscle weakness and signs of neuromuscular disease. Listen Observe Evaluate Test Refer Guide for primary care providers includes: Surveillance Aid: Assessing Weakness
More informationPhysical Therapy Workshop End Duchenne Tour Dallas, TX October 13, 2018
Physical Therapy Workshop End Duchenne Tour Dallas, TX October 13, 2018 Leslie Nelson, PT, PhD University of Texas Southwestern Medical Center Children s Health, Dallas Physical Therapy Standards in Duchenne
More informationMechanical Ventilation of the Patient with Neuromuscular Disease
Mechanical Ventilation of the Patient with Neuromuscular Disease Dean Hess PhD RRT Associate Professor of Anesthesia, Harvard Medical School Assistant Director of Respiratory Care, Massachusetts General
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More informationPENETRANCE ACTIONABILITY SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS. YES ( 1 of above) YES (Proceed to Stage II)
Stage I: Binning Dashboard GENE/GENE PANEL: APC ACTIONABILITY 1. Is there a qualifying resource, such as a practice guideline or systematic review, for the genetic condition? 2. Does the practice guideline
More informationYES NO UNKNOWN. Stage I: Rule-Out Dashboard Secondary Findings in Adults ACTIONABILITY PENETRANCE SIGNIFICANCE/BURDEN OF DISEASE NEXT STEPS
Stage I: Rule-Out Dashboard GENE/GENE PANEL: COL5A1, COL5A2 DISORDER: Ehlers-Danlos Syndrome, Classic Type HGNC ID: 2209, 2210 OMIM ID: 130000 ACTIONABILITY PENETRANCE 1. Is there a qualifying resource,
More information20/11/2013. Dr. Sinead Maguire Neurology Registrar 22 nd November 2013
Dr. Sinead Maguire Neurology Registrar 22 nd November 2013 The active total care of patients whose disease is not responsive to curative treatment. Control of pain, of other symptoms, and psychological,
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationManagement of Spinal Deformities in Spinal Muscular Atrophy
Management of Spinal Deformities in Spinal Muscular Atrophy CURE SMA 2016 Annual Conference 30 June 2017 Samuel R. Rosenfeld, M.D. CHOC CHILDRENS HOSPITAL UNIVERSTY of CALIFORNIA, IRVINE Chest wall deformities
More informationGenetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report
Genetic diagnosis of limb girdle muscular dystrophy type 2A, A Case Report Roshanak Jazayeri, MD, PhD Assistant Professor of Medical Genetics Faculty of Medicine, Alborz University of Medical Sciences
More informationOpinion 9 January 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 9 January 2013 The draft opinion adopted by the Transparency Committee on 7 November 2012 was the subject of a hearing
More informationPrimary Periodic Paralysis. A Complex Disorder. A Challenging Diagnosis.
Primary Periodic Paralysis A Complex Disorder. A Challenging Diagnosis. A Complex Disorder A Group of Rare Channelopathies With Varying Subtypes and Triggers Primary periodic paralysis causes recurrent,
More informationHYPERTROPHIC CARDIOMYOPATHY
HYPERTROPHIC CARDIOMYOPATHY Most often diagnosed during infancy or adolescence, hypertrophic cardiomyopathy (HCM) is the second most common form of heart muscle disease, is usually genetically transmitted,
More informationChapter Goal. Learning Objectives 9/12/2012. Chapter 36. Geriatrics. Use assessment findings to formulate management plan for geriatric patients
Chapter 36 Geriatrics Chapter Goal Use assessment findings to formulate management plan for geriatric patients Learning Objectives Describe dependent & independent living environments Identify local resources
More informationStudent Outline. Improving Transportation Safety: Commercial Driver Medical Examiner Training CHAPTER 1. General FMCSA Information
Student Outline CHAPTER 1 General FMCSA Information FMCSA Mission Statement / Dedicated to Safety / NRCME Important Definitions Regulations Vs. Medical Guidelines Privacy and the Medical Examination 13
More informationInfantile-onset glycogen storage disease type II
Case Report 379 Infantile-Onset Glycogen Storage Disease Type II (Pompe Disease): Report of a Case with Genetic Diagnosis and Pathological Findings Yao-Tun Teng, MD; Wen-Jen Su, MD; Jia-Wei Hou 1, MD,
More informationGuidelines for exercise and orthoses in children with neuromuscular disorders
Guidelines for exercise and orthoses in children with neuromuscular disorders These guidelines were drawn following a workshop held in Newcastle 2002. Several experts from different disciplines including
More informationRehabilitation and psychosocial aspects in DMD care
Rehabilitation and psychosocial aspects in DMD care Budapest, 18-04-2012 Birgit F. Steffensen, Physiotherapist, PhD The National Danish Rehabilitation Centre for Neuromuscular Diseases Denmark Demographics:
More informationCongenital myasthenic syndromes (CMS)
Congenital myasthenic syndromes (CMS) This fact sheet is for children and adults diagnosed with congenital myasthenic syndrome. It s a complex subject, so information has been adapted to suit all audiences.
More informationParamedic Rounds. Pre-Hospital Continuous Positive Airway Pressure (CPAP)
Paramedic Rounds Pre-Hospital Continuous Positive Airway Pressure (CPAP) Morgan Hillier MD Class of 2011 Dr. Mike Peddle Assistant Medical Director SWORBHP Objectives Outline evidence for pre-hospital
More informationA PHYSIATRIC APPROACH TO PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
A PHYSIATRIC APPROACH TO PATIENTS WITH FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY SUSAN KEESHIN M.D. MEDICAL DIRECTOR DAY REHAB THE SHIRLEY RYAN ABILITY LAB (FORMERLY KNOWN AS RIC) WHAT IS A PHYSIATRIST AND
More informationThere are four different forms of Tarui disease, which are classed by their signs and symptoms and age of presentation.
Tarui Disease Tarui disease (also known as phosphofructokinase deficiency, or glycogen storage disease type VII) was first described in 1965 by the Japanese physician Seiichiro Tarui and his co-workers.
More informationAmerican Board of Physical Medicine & Rehabilitation. Part I Curriculum & Weights
American Board of Physical Medicine & Rehabilitation Part I Curriculum & Weights Neurologic Disorders 30% Stroke Spinal Cord Injury Traumatic Brain Injury Neuropathies a) Mononeuropathies b) Polyneuropathies
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationCervical Plating Lumbar Microdiscectomy SCOLIOSIS
SCOLIOSIS Introduction Scoliosis is the term given to abnormal lateral curvature of the spine when looked from front or back. If diagnosed early then it could be treated conservatively through bracing
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is mandated and administered by the Illinois Department of
More informationGeneral principles of physiologic conditioning
General principles of physiologic conditioning - Physiologic conditioning refers to a planned program of exercise directed toward improving the functional capacity of a particular bodily system - 4 principles
More informationNeuromuscular diseases (NMDs) include both hereditary and acquired diseases of the peripheral neuromuscular system. They are diseases of the
Neuromuscular diseases (NMDs) include both hereditary and acquired diseases of the peripheral neuromuscular system. They are diseases of the peripheral nerves (neuropathies and anterior horn cell diseases),
More informationWhy You (and Your Insurance Company) Need to Get Your Child Standing by Susan Agrawal
www.complexchild.com Why You (and Your Insurance Company) Need to Get Your Child Standing by Susan Agrawal Fractures. Constipation. Hips out of their sockets. Tight hamstrings. Orthopedic surgery. Casts
More informationNemaline (rod) myopathies
Nemaline (rod) myopathies Nemaline, or rod, myopathies are a group of conditions which fall under the umbrella of congenital myopathies. They are characterised by rod-like structures in the muscle cells,
More informationMotor Neurone Disease NICE to manage Management of ineffective cough. Alex Long Specialist NIV/Respiratory physiotherapist June 2016
Motor Neurone Disease NICE to manage Management of ineffective cough Alex Long Specialist NIV/Respiratory physiotherapist June 2016 Content NICE guideline recommendations Respiratory involvement in MND
More informationGuidelines for exercise and orthoses in children with neuromuscular disorders
Guidelines for exercise and orthoses in children with neuromuscular disorders These guidelines were drawn following a workshop held in Newcastle 2002. Several experts from different disciplines including
More informationScoliosis. About idiopathic scoliosis and its treatment. Patient and Family Education. What types of scoliosis are there?
Patient and Family Education Scoliosis About idiopathic scoliosis and its treatment This handout covers the most common type of scoliosis, adolescent idiopathic scoliosis. Other types of scoliosis may
More informationKNIEST DYSPLASIA NATURAL HISTORY
KNIEST DYSPLASIA NATURAL HISTORY Richard M. Pauli, M.D., Ph.D., Midwest Regional Bone Dysplasia Clinics revised 8/2009 INTRODUCTION: The following summary of the medical expectations in Kniest Dysplasia
More informationMyotubular (centronuclear) myopathy
Myotubular (centronuclear) myopathy Myotubular, or centronuclear, myopathy falls under the umbrella of congenital myopathies. It is characterised by a specific pattern in the muscle tissue when viewed
More informationOBJECTIVES. Unit 7:5 PROPERTIES OR CHARACTERISTICS OF MUSCLES. Introduction. 3 Kinds of Muscles. 3 Kinds of Muscles 4/17/2018 MUSCULAR SYSTEM
OBJECTIVES Unit 7:5 MUSCULAR SYSTEM Compare the three main kinds of muscles by describing the action of each Differentiate between voluntary and involuntary muscles List at least three functions of muscles
More informationPart 2: Exercise Treatment for Duchenne MD
Part 2: Exercise Treatment for Duchenne MD Duchenne MD A progressive loss of muscle function Females are carriers of the disease and only males are affected X-linked Affects 1 in 3600 boys Symptoms appear
More informationPreventing Respiratory Complications of Muscular Dystrophy
Preventing Respiratory Complications of Muscular Dystrophy Jonathan D. Finder, MD Professor of Pediatrics University of Pittsburgh School of Medicine Children s Hospital of Pittsburgh Introduction Respiratory
More informationPhenotype linkages to NMD common data elements
TREAT-NMD Global Database Oversight Committee and Curators Meeting 19 th -20th September 2016 - Leuven, Belgium Phenotype linkages to NMD common data elements Prof. C. Béroud & Dr. D. Salgado "Genetics
More informationMuscular System. Disorders & Conditions
Muscular System Disorders & Conditions Fibromyalgia Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Often is described
More informationMuscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation
Muscular Dystrophy UK s Adult North Star Network Care recommendations for adults with Duchenne a consultation Background: The North Star Network was set up in 2003 to help drive improvements in services
More informationThe Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE
JIMD Reports DOI 10.1007/8904_2012_148 RESEARCH REPORT The Changing Face of Infantile Pompe Disease: A Report of Five Patients from the UAE Waseem Fathalla Elamin Ahmed Received: 02 July 2011 /Revised:
More informationGlycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency
Glycogen Storage Disease Type III also known as Cori or Forbe s Disease/Debrancher Enzyme Deficiency What is GSDIII? Glycogen Storage Disease type 3 is an inherited condition caused by a defect in a gene
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationAssociation of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4
jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationAlzheimer s Disease, Dementia, Related Disorders
Alzheimer s Disease, Dementia, Related Disorders Stage 7 on the FAST Scale signifies the threshold of activity limitation that would support a six-month prognosis. The FAST Scale does not address the impact
More informationBIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1
BIPN100 F15 Human Physiol I (Kristan) Lecture 14 Cardiovascular control mechanisms p. 1 Terms you should understand: hemorrhage, intrinsic and extrinsic mechanisms, anoxia, myocardial contractility, residual
More informationabstract SUPPLEMENT ARTICLE
Management of Confirmed Newborn- Screened Patients With Pompe Disease Across the Disease Spectrum David F. Kronn, MD, a Debra Day-Salvatore, MD, b Wuh-Liang Hwu, MD, PhD, c Simon A. Jones, MBChB, BSc,
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationA Lawyer s Perspective on Genetic Screening Performed by Cryobanks
A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child
More informationDiseases of Muscle and Neuromuscular Junction
Diseases of Muscle and Neuromuscular Junction Diseases of Muscle and Neuromuscular Junction Neuromuscular Junction Muscle Myastenia Gravis Eaton-Lambert Syndrome Toxic Infllammatory Denervation Atrophy
More informationAgeing with Spinal Cord Injury
Ageing with Spinal Cord Injury A Resource for Health Service Providers WA State Spinal Injury Unit Version 1 October 2013 Review Date October 2016 This document has been developed to provide health service
More informationValue of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018
Value of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018 Disclosures Scientific Advisory Board: Biogen, Cytokinetics, Roche, Acceleron Consultation: Roche, Audentes,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationOverview of COPD INTRODUCTION
Overview of COPD INTRODUCTION Chronic obstructive pulmonary disease (COPD) is a common lung disease that affects millions of people, and it is the fourth leading cause of death in the United States. It
More informationPreoperative Pulmonary Evaluation. Michelle Zetoony, DO, FCCP, FACOI Board Certified Pulmonary, Critical Care, Sleep and Internal Medicine
Preoperative Pulmonary Evaluation Michelle Zetoony, DO, FCCP, FACOI Board Certified Pulmonary, Critical Care, Sleep and Internal Medicine No disclosures related to this lecture. Objectives Identify pulmonary
More informationSelf-study course. Pneumonia
Self-study course Pneumonia This brochure is available in alternate formats. Call 1-800-282-8096 (V/TTY) 2 Course objectives: At the end of this course you will be able to: 1) Identify a series of steps
More informationNeonatal Hypotonia. Encephalopathy acute No encephalopathy. Neurology Chapter of IAP
The floppy infant assumes a frog legged position. On ventral suspension, the baby can not maintain limb posture against gravity and assumes the position of a rag doll. Encephalopathy acute No encephalopathy
More informationFatty Acid Oxidation Disorders
Genetic Fact Sheets for Parents Fatty Acid Oxidation Disorders Screening, Technology, and Research in Genetics is a multi-state project to improve information about the financial, ethical, legal, and social
More informationHow are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms
How are unresolved Myasthenia Gravis symptoms disrupting your day? Talk to your doctor about your symptoms Recognize the symptoms of your generalized Myasthenia Gravis (gmg) Anti-acetylcholine receptor
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease By: Dr. Fatima Makee AL-Hakak () University of kerbala College of nursing Out lines What is the? Overview Causes of Symptoms of What's the difference between and asthma?
More informationActivity and Exercise
Activity and Exercise Chapter 44 Ra'eda Almashaqba 1 Activity and Exercise refers to the persons rotten of exercise, activity, leisure, and recreation Include: 1. Activity of daily living 2. The type,
More informationNational Sleep Disorders Research Plan
Research Plan Home Foreword Preface Introduction Executive Summary Contents Contact Us National Sleep Disorders Research Plan Return to Table of Contents SECTION 5 - SLEEP DISORDERS SLEEP-DISORDERED BREATHING
More informationCHAPTER 3. The Human Body National Safety Council
CHAPTER 3 The Human Body The Human Body Composed of many different organs and tissues All parts work together: To sustain life Allow activity Injury or illness impairs functions 3-3 Cranial located in
More informationCHEST PAIN IS MY CHILD GOING. Thomas C. Martin MD, FAAP, FACC EMMC Pediatric Cardiology Eastern Maine Medical Center Bangor, Maine
CHEST PAIN IN CHILDREN: IS MY CHILD GOING TO DIE? Thomas C. Martin MD, FAAP, FACC EMMC Pediatric Cardiology Eastern Maine Medical Center Bangor, Maine DISCLAIMER Presentation t ti at the Maine Chapter,
More information